Tokyo (October 19, 2017) - Konica Minolta, Inc. and Innovation Network Corporation of Japan today announced the close of their joint acquisition of Ambry Genetics Corporation (“Ambry”) on October 19, 2017 (JST). Known as a pioneer and thought leader in genetic testing, Ambry is the first laboratory in the world to offer hereditary cancer panels and clinical exome sequencing.

This strategic acquisition was announced on July 6, 2017. Through this acquisition, Konica Minolta and INCJ will accelerate the precision medicine business by creating a new medical platform to improve patients’ quality of life while also saving the healthcare system money.

Ambry chose to partner with Konica Minolta to accelerate the development of new diagnostic tests for many different diseases for patients throughout the world. Together they have the combined resources, technology, and scale to advance biomedical research on a global scale, resulting in better tests for doctors and more precise treatments for their patients.